Health and Fitness Health and Fitness
Mon, February 13, 2012
Sun, February 12, 2012
Fri, February 10, 2012
Thu, February 9, 2012
Wed, February 8, 2012
[ Wed, Feb 08th 2012 ] - Market Wire
Imaging3 Updates Website
Tue, February 7, 2012
Mon, February 6, 2012
Sun, February 5, 2012
[ Sun, Feb 05th 2012 ] - Market Wire
30 a.m. ET
Sat, February 4, 2012
Fri, February 3, 2012
Thu, February 2, 2012
Wed, February 1, 2012
Tue, January 31, 2012

DURECT to Present at the BIO CEO amp;; Investor Conference


//health-fitness.news-articles.net/content/2012/ .. t-the-bio-ceo-amp-59-59-investor-conference.html
Published in Health and Fitness on Tuesday, February 7th 2012 at 9:15 GMT by Market Wire   Print publication without navigation


DURECT to Present at the BIO CEO & Investor Conference -- CUPERTINO, Calif., Feb. 7, 2012 /PRNewswire/ --

DURECT to Present at the BIO CEO & Investor Conference

[ ]

CUPERTINO, Calif., Feb. 7, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: [ DRRX ]) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 14 at 10:30 a.m. Eastern Time.  The conference is being held at the Waldorf-Astoria Hotel in New York City. 

(Logo:  [ http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ])

A live audio webcast of the presentation will be available by accessing [ http://www.veracast.com/webcasts/bio/ceoinvestor2012/61206433.cfm ].  A live audio webcast of the presentation will also be available by accessing DURECT's homepage at [ www.durect.com ] and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit [ www.durect.com ].

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, ELADUR™ and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

[ Back to top ]

RELATED LINKS
[ http://www.durect.com ]


Publication Contributing Sources